Evidence map›Paper›PMID 28785914›Full record

ArticlePharmaceutical research2017

Precision Ocular Drug Delivery Via Aerosol Ring Vortices.

Matthew J Herpin, Hugh D C Smyth

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew J HerpinDivision of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 W. University Avenue, Campus Mail Code A1902, Austin, TX, 78712, USA.
Hugh D C SmythDivision of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 W. University Avenue, Campus Mail Code A1902, Austin, TX, 78712, USA. hugh.smyth@austin.utexas.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite being the most prominent dosage form for topical ocular delivery, eye-drops have several well-recognized drawbacks. Addressing these limitations, in this work we introduce a novel method to accurately deliver ophthalmic medications to the surface of the eye at relatively low volume and low velocity. By aerosolizing a medicament and dispensing it in the form of a toroidal vortex, commonly known as a "smoke ring", several major drawbacks associated with topical drug delivery can be avoided.

methodsA device capable of emitting a toroidal vortex was developed such that actuation force and aerosol loading could be modulated. Different solution formulations were tested for deposited dose on an in vitro eye.

resultsIt was found that the dose delivered to the surface of an in vitro eye was directly proportional to the velocity and the size of the droplets emitted from the device. With a dilute solution formulation (0.05% fluorescein sodium), doses could be reproducibly deposited by actuating the device at different velocities (from ~5 ng to ~18 ng per actuation). While a more concentrated solution of 0.5% fluorescein sodium, between 20 ng and 160 ng could be deposited depending on selected actuation velocity. And with the highest concentration, 5% fluorescein sodium, 1.15 +/- 0.075 μg was deposited. It was also shown that the amount of drug deposited onto the eye surface could be modulated by modulating the chamber fill time.

conclusionPrecise toroidal vortex based aerosol delivery may facilitate optimized administration of medicines to the surface of the eye.

Indexed as

Administration, OphthalmicAerosolsChemistry, PharmaceuticalDrug Delivery SystemsDrug LiberationEquipment DesignFluoresceinOphthalmic SolutionsParticle SizeAerosolsFluoresceinOphthalmic Solutionsaerosoldrug-device combination productsmicro-volume drug deliveryocular drug deliverytoroidal vortex

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.